Literature DB >> 15353914

Acute normovolemic hemodilution does not reduce antithrombin concentration for cardiac surgery.

Matthew Dean Linden1, Mark Schneider, Wendy Naomi Erber.   

Abstract

BACKGROUND: Acute normovolemic hemodilution (ANH) is used to reduce allogeneic blood transfusion with cardiac surgery. This procedure involves pre-operatively removing and storing a volume of whole blood and replacing the volume with crystalloid. The stored blood is then available for transfusion, if required. Hemodilution associated with ANH may reduce the effectiveness of heparin anticoagulation due to dilution of antithrombin. The aim of this study was to determine if antithrombin concentrations are reduced in patients who undergo one unit of ANH during cardiac surgery.
METHODS: Patients scheduled for cardiac surgery (n = 71) were grouped according to whether they did or did not undergo ANH pre-operatively. Antithrombin concentrations were measured before and after ANH. This study had 80% power to detect a difference in reduction of antithrombin concentration of 6% between groups following ANH with an alpha error of <0.05. The effect of one unit ANH was expected to cause a difference of 12% or greater.
RESULTS: No significant difference in the concentration of antithrombin between ANH patients and those that did not have ANH, nor was there a difference in the decrease in antithrombin between groups.
CONCLUSIONS: The results indicate that one unit of ANH does not significantly reduce the concentration of antithrombin prior to cardiac surgery. Thus patients who undergo one unit of ANH are not at increased risk due to dilution of antithrombin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353914     DOI: 10.1023/B:THRO.0000040485.78749.d7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  29 in total

1.  Transfusion practices must be evidence-based.

Authors:  K M McGrath
Journal:  Med J Aust       Date:  2001-03-19       Impact factor: 7.738

2.  Safety first: reducing exposure to allogeneic blood.

Authors:  R W Beal
Journal:  Med J Aust       Date:  2000-04-17       Impact factor: 7.738

3.  Use of interventions to minimise perioperative allogeneic blood transfusion in Australia. A survey by the International Study of Perioperative Transfusion (ISPOT) Study Group.

Authors:  D A Henry; K M Henderson; J L Fryer; C J Treloar; K M McGrath; S F Deveridge
Journal:  Med J Aust       Date:  2000-04-17       Impact factor: 7.738

4.  Haemodilution enhances coagulation.

Authors:  T G Ruttmann
Journal:  Br J Anaesth       Date:  2002-04       Impact factor: 9.166

5.  INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.

Authors:  O EGEBERG
Journal:  Thromb Diath Haemorrh       Date:  1965-06-15

Review 6.  Acute normovolaemic haemodilution.

Authors:  J Gillon; M Desmond; M J Thomas
Journal:  Transfus Med       Date:  1999-09       Impact factor: 2.019

7.  Changes in the coagulation and fibrinolytic systems during and after cardiopulmonary bypass surgery.

Authors:  U E Kongsgaard; N Smith-Erichsen; O Geiran; L Bjørnskau
Journal:  Thorac Cardiovasc Surg       Date:  1989-06       Impact factor: 1.827

8.  The effect of haemodilution on antithrombin concentration during cardiac surgery.

Authors:  M D Linden; N M Gibbs; M Bremner; M Schneider; W N Erber
Journal:  Anaesth Intensive Care       Date:  2004-04       Impact factor: 1.669

9.  Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation.

Authors:  T F Slaughter; J B Mark; H El-Moalem; K A Hayward; A K Hilton; L P Hodgins; C S Greenberg
Journal:  Blood Coagul Fibrinolysis       Date:  2001-01       Impact factor: 1.276

10.  In vivo behavior of human radioiodinated antithrombin III: distribution among three physiologic pools.

Authors:  T H Carlson; T L Simon; A C Atencio
Journal:  Blood       Date:  1985-07       Impact factor: 22.113

View more
  1 in total

1.  Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution.

Authors:  Jung Min Lee; Eun Young Park; Kyung Mi Kim; Jong Chan Won; Tack Koon Jung; Soo Kyung Lee
Journal:  J Int Med Res       Date:  2017-10-04       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.